Medical device marketers evolve for a post-COVID future
As face-to-face access to decision-makers remains elusive, medical device marketers are evolving their tactics for a post-COVID future.
Device
Five things for pharma marketers to know: Friday, January 5, 2018
Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise
Five things for pharma marketers to know: Wednesday, January 3, 2018
Utah Senator who backed Orphan Drug Act will not seek reelection; medicines more expensive in 2018; Spark’s genetic therapy for rare blindness costs $850,000
Five things for pharma marketers to know: Wednesday, December 13, 2017
Teva diminishes debt with job cuts and sale; FDA to study whether consumers can detect misleading ads; AbbVie, Roche present positive Phase-III data at ASH
GCI Health puts Edie DeVine in charge of medical, health tech
DeVine will oversee the agency’s health IT and medical device work.
Five things for pharma marketers to know: Tuesday, November 14, 2017
FDA approves first digital pill; biotech companies race to develop cancer-fighting microbiome drugs; Loxo and Bayer reach $1.55 billion deal for rare cancer drugs
Five things for pharma marketers to know: Monday, July 31, 2017
FDA launches digital health pre-certification pilot; J&J’s experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi
Why Philips’ Erik Hollander turned to reinvention
He describes his current charge as “transforming a more creative occupation into a science.”
What uncertainty? 72% of health marketers say 2017 budgets are up
This according to the 172 healthcare marketing executives who participated in the 2017 MM&M/Guidemark Health Healthcare Marketers Trend Report.
Five things for pharma marketers to know: Wednesday, January 25, 2017
Novartis forecasts slower growth in 2017; Actelion reports trial failure for PAH drug; HHS nominee Tom Price denies conflict of interest claims
